MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Ruxolitinib
Related studies linked through entity extraction aliases.
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Status
- RECRUITING
- Phase
- PHASE1
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
- Status
- RECRUITING
- Phase
- PHASE1
JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum Disorders
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV
- Status
- RECRUITING
- Phase
- PHASE2
Ruxolitinib in Patients With Myelofibrosis
- Status
- UNKNOWN
- Phase
- N/A
Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)
- Status
- RECRUITING
- Phase
- PHASE2
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
- Status
- RECRUITING
- Phase
- PHASE1
Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease
- Status
- COMPLETED
- Phase
- PHASE3
De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model
- Status
- COMPLETED
- Phase
- PHASE2
Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model
- Status
- RECRUITING
- Phase
- PHASE2
Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.
- Status
- TERMINATED
- Phase
- PHASE2